Scholarlink

Background <p>This study aimed to investigate the efficacy and safety of fruquintinib plus sintilimab in mismatch repair-proficient (pMMR)/microstatellite stable (MSS) refractory metastatic colorectal cancer (mCRC).</p> Methods <p>Patients with pMMR/MSS mCRCs who had failed at least 2 lines of standard therapy were enrolled and treated with fruquintinib plus sintilimab in this single arm, phase II clinical trial. The primary endpoint was the 6&#xa0;month progression-free survival (PFS) rate.</p> Results <p>A total of 75 patients were included, all of whom had been previously treated with bevacizumab. The 6&#xa0;month PFS rate was 33.3%. The median PFS (mPFS) was 4.1&#xa0;months, the median overall survival (mOS) was 15.3&#xa0;months, the objective response rate (ORR) was 12.5%, and the disease control rate (DCR) was 76.4%. Treatment-related adverse events (TRAEs) occurred in 94.7%, with 18.7% being grade 3 or 4. There were no treatment-related deaths. Patients had a significantly shorter mPFS compared to those without liver metastasis (3.2 versus 7.6&#xa0;months, <i>P</i> &lt; 0.001). Incorporating Eastern Cooperative Oncology Group (ECOG) score further improved its predictive value for PFS. Those in the high-albumin group showed significantly longer mOS (25.9 versus 11.0&#xa0;months, <i>P</i> = 0.024), while the high-neutrophil-to-lymphocyte ratio (NLR) group exhibited a significantly shorter mOS (9.3 versus 19.3&#xa0;months, <i>P</i> = 0.033).</p> Conclusions <p>Fruquintinib plus sintilimab showed promising activity and good tolerability in refractory pMMR/MSS mCRC. Liver metastasis was a negative predictor for efficacy and PFS, especially when combined with the ECOG score. Higher baseline albumin and lower NLR predicted longer OS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月20日

查看全文
  • Wen. Zhang,
  • Cai-Feng. Gong,
  • Jing-Long. Huang,
  • Tian-Yi. Liu,
  • Yong-Kun. Sun,
  • Zhi-Chao. Jiang,
  • Wang. Qu,
  • Lin. Yang,
  • Ying. Xin,
  • Fei-Long. Zhao,
  • Yue-zong. Bai,
  • Ai-Ping. Zhou

摘要

Background

This study aimed to investigate the efficacy and safety of fruquintinib plus sintilimab in mismatch repair-proficient (pMMR)/microstatellite stable (MSS) refractory metastatic colorectal cancer (mCRC).

Methods

Patients with pMMR/MSS mCRCs who had failed at least 2 lines of standard therapy were enrolled and treated with fruquintinib plus sintilimab in this single arm, phase II clinical trial. The primary endpoint was the 6 month progression-free survival (PFS) rate.

Results

A total of 75 patients were included, all of whom had been previously treated with bevacizumab. The 6 month PFS rate was 33.3%. The median PFS (mPFS) was 4.1 months, the median overall survival (mOS) was 15.3 months, the objective response rate (ORR) was 12.5%, and the disease control rate (DCR) was 76.4%. Treatment-related adverse events (TRAEs) occurred in 94.7%, with 18.7% being grade 3 or 4. There were no treatment-related deaths. Patients had a significantly shorter mPFS compared to those without liver metastasis (3.2 versus 7.6 months, P < 0.001). Incorporating Eastern Cooperative Oncology Group (ECOG) score further improved its predictive value for PFS. Those in the high-albumin group showed significantly longer mOS (25.9 versus 11.0 months, P = 0.024), while the high-neutrophil-to-lymphocyte ratio (NLR) group exhibited a significantly shorter mOS (9.3 versus 19.3 months, P = 0.033).

Conclusions

Fruquintinib plus sintilimab showed promising activity and good tolerability in refractory pMMR/MSS mCRC. Liver metastasis was a negative predictor for efficacy and PFS, especially when combined with the ECOG score. Higher baseline albumin and lower NLR predicted longer OS.